Kumar Naresh, Dey Chinmoy S
Signal Transduction Research Laboratory, Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Punjab, India.
Br J Pharmacol. 2002 Oct;137(3):329-36. doi: 10.1038/sj.bjp.0704878.
1 Metformin lowers blood glucose levels in type 2 diabetic patients. To evaluate the insulin sensitizing action of metformin on skeletal muscle cells, we have used C2C12 skeletal muscle cells differentiated in chronic presence or absence of insulin. 2 Metformin was added during the last 24 h of differentiation of the C2C12 myotubes. Insulin-stimulated tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) was determined. 3 Chronic insulin treatment resulted in 60 and 40% reduction in insulin-stimulated tyrosine phosphorylation of IR and IRS-1, respectively. Treatment with metformin was able to increase the tyrosine phosphorylation of IR and IRS-1 by 100 and 90% respectively. 4 Chronic insulin treatment drastically reduced (45%) insulin-stimulated phosphatidyl inositol 3-kinase (PI 3-kinase) activity. Metformin treatment restored PI 3-kinase activity in insulin-resistant myotubes. 5 Insulin-stimulated glucose uptake was impaired in chronically insulin-treated myotubes. Metformin increased basal glucose uptake to significant levels (P<0.05), but metformin did not increase insulin-stimulated glucose transport. 6 All the three mitogen-activated protein kinases (MAPK) were activated by insulin in sensitive myotubes. The activation of p38 MAPK was impaired in resistant myotubes, while ERK and JNK were unaffected. Treatment with metformin enhanced the basal activation levels of p38 in both sensitive and resistant myotubes, but insulin did not further stimulate p38 activation in metformin treated cells. 7 Treatment of cells with p38 inhibitor, SB203580, blocked insulin- and metformin-stimulated glucose uptake as well as p38 activation. 8 Since the effect of metformin on glucose uptake corresponded to p38 MAPK activation, this suggests the potential role p38 in glucose uptake. 9 These data demonstrate the direct insulin sensitizing action of metformin on skeletal muscle cells.
1 二甲双胍可降低2型糖尿病患者的血糖水平。为评估二甲双胍对骨骼肌细胞的胰岛素增敏作用,我们使用了在持续存在或不存在胰岛素的情况下分化的C2C12骨骼肌细胞。2 在C2C12肌管分化的最后24小时添加二甲双胍。测定胰岛素刺激的胰岛素受体(IR)和胰岛素受体底物-1(IRS-1)的酪氨酸磷酸化。3 长期胰岛素治疗分别导致胰岛素刺激的IR和IRS-1酪氨酸磷酸化降低60%和40%。二甲双胍治疗能够分别使IR和IRS-1的酪氨酸磷酸化增加100%和90%。4 长期胰岛素治疗显著降低(45%)胰岛素刺激的磷脂酰肌醇3-激酶(PI 3-激酶)活性。二甲双胍治疗可恢复胰岛素抵抗肌管中的PI 3-激酶活性。5 长期胰岛素治疗的肌管中胰岛素刺激的葡萄糖摄取受损。二甲双胍将基础葡萄糖摄取增加到显著水平(P<0.05),但二甲双胍并未增加胰岛素刺激的葡萄糖转运。6 在敏感肌管中,所有三种丝裂原活化蛋白激酶(MAPK)均被胰岛素激活。在抗性肌管中,p38 MAPK的激活受损,而ERK和JNK未受影响。二甲双胍治疗增强了敏感和抗性肌管中p38的基础激活水平,但胰岛素在二甲双胍处理的细胞中并未进一步刺激p38激活。7 用p38抑制剂SB203580处理细胞可阻断胰岛素和二甲双胍刺激的葡萄糖摄取以及p38激活。8 由于二甲双胍对葡萄糖摄取的作用与p38 MAPK激活相对应,这表明p38在葡萄糖摄取中具有潜在作用。9 这些数据证明了二甲双胍对骨骼肌细胞的直接胰岛素增敏作用。